[Clinico-experimental study of a new antibactorial agent for local use in stomatology]

Tibezonium iodide is a new drug having antibacterial activity for the therapy and the prevention of mouth infections. Before testing its therapeutic efficacy, its effect on the bacterial flora of the human saliva was verified as follows. Salivary samples, collected before and after the administration (double-blind, cross-over) to volunteers, were counted for bacteria. The drug reduced the bacterial count in the saliva with statistical significance in both the pharmaceutical forms. Subsequently the drug was tested in different dental or oral conditions. To 90 patients suffering from marginal paradentitis or other diseases with this type of complications tablets were administered. The results obtained in this group were satisfactory or almost satisfactory in 73.5% of the cases examined. The patients treated with bubble-gums were 70. All of them were suffering from the same kind of disease of the first group; a few of them had alveolitis following tooth extraction. The results in these subjects were satisfactory or almost satisfactory in 77% of the cases examined. Tibezonium proved to be particularly effective in marginal paradentitis and in piorrhoic paradontosis. Bubble-gums should not be used in subjects with dental mobile prosthesis.